Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

FBTAX vs. BIB: which is better?

Bottom line

FBTAX vs BIB: the short answer

FBTAX (Fidelity Advisor Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 26% of their top holdings (by weight) are shared.

But BIB is far broader, holding 267 positions to 129 for FBTAX, so beyond the top names it adds exposure FBTAX doesn't have.

FBTAX is cheaper at 0.94% vs 0.95% — a difference of $1.00 a year per $10,000 invested.

Over five years, FBTAX returned +6.4% a year vs −1.0% for BIB (reporting dates differ).

Updated Nov 19, 2026

FBTAX vs BIB side by side

FBTAXBIB
TypeMutual fundETF
Fund familyFidelityProShares
CategoryTechnology SectorTechnology Sector
Expense ratio0.94%0.95%
Annual cost per $10k$94$95
10-yr cost on $10k (prospectus)$1,663$1,401
Max front load—None
12b-1 fee0.25%—
1-yr return+31.5%+59.3%
5-yr return (annualized)+6.4%−1.0%
10-yr return (annualized)+7.7%+1.4%
Best quarter+30.3%+56.2%
Worst quarter−27.8%−42.7%
Net assets (fund)$2.2B$73.7M
Number of holdings129267
Portfolio turnover54%29%
Returns as ofSep 30, 2026Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearFBTAXBIBDifference
2025+39.6%+59.3%−19.8%
2024+5.3%−10.0%+15.3%
2023+10.7%−1.3%+12.0%
2022−8.0%−28.6%+20.7%
2021−3.6%−5.9%+2.4%
2020+32.2%+39.7%−7.6%
2019+25.7%+45.5%−19.8%
2018−3.8%−24.4%+20.6%
2017+25.8%+40.8%−15.0%
2016−23.6%−44.2%+20.7%

Source: Fund prospectus bar charts

Holdings overlap

9 of FBTAX's top 25 holdings also appear in BIB's top 25.

Shared top holdings
HoldingFBTAXBIB
Gilead Sciences Inc5.70%4.66%
Alnylam Pharmaceuticals Inc3.62%2.01%
Insmed Inc3.05%1.16%
Revolution Medicines Inc3.00%1.57%
Argenx Se3.00%1.19%
Biogen Inc2.71%1.44%
Amgen Inc2.37%4.48%
Moderna Inc1.60%0.94%
Vertex Pharmaceuticals Inc1.39%4.65%

Source: SEC Form N-PORT

FBTAX top 10

  1. Abbvie Inc — 14.71%
  2. Gilead Sciences Inc — 5.70%
  3. Spyre Therapeutics Inc — 3.83%
  4. Alnylam Pharmaceuticals Inc — 3.62%
  5. Dianthus Therapeutics Inc — 3.55%
  6. Cogent Biosciences Inc — 3.25%
  7. Oruka Therapeutics Inc — 3.24%
  8. Insmed Inc — 3.05%
  9. Revolution Medicines Inc — 3.00%
  10. Argenx Se — 3.00%

BIB top 10

  1. N/a — 7.35%
  2. ProShares GENIUS Money Market ETF — 6.80%
  3. Gilead Sciences, Inc. — 4.66%
  4. Vertex Pharmaceuticals, Inc. — 4.65%
  5. Amgen, Inc. — 4.48%
  6. N/a — 3.94%
  7. N/a — 3.26%
  8. Regeneron Pharmaceuticals, Inc. — 3.21%
  9. N/a — 2.62%
  10. Alnylam Pharmaceuticals, Inc. — 2.01%

FAQ

What is the difference between FBTAX and BIB?
FBTAX (Fidelity Advisor Biotechnology Fund) and BIB (ProShares Ultra Nasdaq Biotechnology) are quite different portfolios: only about 26% of their top holdings (by weight) are shared. But BIB is far broader, holding 267 positions to 129 for FBTAX, so beyond the top names it adds exposure FBTAX doesn't have.
Which is cheaper, FBTAX or BIB?
FBTAX has the lower expense ratio (0.94%).
Should I own both FBTAX and BIB?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.